

# Enhanced Annual Drug List Updates

October 2019

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
INBRIJA (levodopa inhal powder cap 42 mg)	Brand	Addition, Preferred Status
KALYDECO (ivacaftor packet 25 mg)	Brand	Addition, Preferred Status
MAYZENT (siponimod fumarate tab 0.25 mg (base equiv))	Brand	Addition, Preferred Status
MAYZENT (siponimod fumarate tab 2 mg (base equiv))	Brand	Addition, Preferred Status
SKYRIZI (risankizumab-rzaa sol prefilled syringe 2 x 75 mg/0.83ml kit)	Brand	Addition, Preferred Status
SYMDEKO (tezacaftor-ivacaftor 50-75 mg & ivacaftor 75 mg tab tbpk)	Brand	Addition, Preferred Status
SYMJEPI (epinephrine soln prefilled syringe 0.15 mg/0.3ml (1:2000))	Brand	Addition, Preferred Status
SYMJEPI (epinephrine solution prefilled syringe 0.3 mg/0.3ml (1:1000))	Brand	Addition, Preferred Status
TREMIFYA (guselkumab soln pen-injector 100 mg/ml)	Brand	Addition, Preferred Status
TREMIFYA (guselkumab soln prefilled syringe 100 mg/ml)	Brand	Addition, Preferred Status

Blue Cross and Blue Shield of Illinois (BCBSIL), Blue Cross and Blue Shield of Montana (BCBSMT), Blue Cross and Blue Shield of New Mexico (BCBSNM), Blue Cross and Blue Shield of Oklahoma (BCBSOK), and Blue Cross and Blue Shield of Texas (BCBSTX) are Divisions of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX contract with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSIL, BCBSMT, BCBSNM, BCBSOK, and BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, have an ownership interest in Prime Therapeutics LLC.